Glenmark signs an exclusive multi‑regional license with Hansoh Pharma for Aumolertinib, a third‑generation EGFR‑TKI for NSCLC, expanding its oncology portfolio.
AI Assistant
Glenmark Pharmaceuticals Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.